APACMed
The voice of MedTech

ANNUAL REPORT 2024

APACMed strives to continuously improve the standards of care for patients through innovative collaborations among stakeholders to jointly shape the future of healthcare in the Asia Pacific.

Annual Report 2024

CONTENTS

APACMed
Annual Report 2024

04 ABOUT APACMED

06 FOREWORD

- 06 Chairman - John Collings
- 07 CEO - Harjit Gill

09 APACMED IN NUMBERS

10 PAPERS PUBLISHED

12 COMMITTEE REPORTS

- 12 Government Affairs and Policy Committee
- 14 Market Access Committee
- 16 Regulatory Affairs Committee
- 18 Health Data Committee
- 20 Start-up Committee
- 22 AI Working Group
- 24 ESG Working Group
- 26 NGS Working Group
- 28 APACMed China Office
- 30 APACMed India Office

32 MEDTECH FORUM 2024

34 KEY RESOURCES

36 OUR MEMBERS

40 BOARD OF DIRECTORS

42 SECRETARIAT

The voice of MedTech

ABOUT APACMED

WHO WE ARE?

Founded in 2014 and headquartered in Singapore, APACMed represents the medical technology industry in Asia Pacific, including manufacturers and suppliers of medical equipment, devices, services and in-vitro diagnostics. Providing a unified voice for the industry, APACMed works proactively with policymakers and stakeholders to demonstrate the value of medical technology, promote innovation, and impact policy that advances healthcare access for patients in Asia Pacific.

Visit APACMed online at **www.apacmed.org**

Our Mission

WHAT WE DO?

APACMed strives to continuously improve the standards of care for patients through innovative collaborations among stakeholders to jointly shape the future of healthcare in the Asia Pacific.

Our Strategic Pillars

FOCUS AREAS

ACCESS

We strive to improve access to high quality healthcare for patients through close collaborations with our members and the wider ecosystem stakeholders to help shape policies that truly impact the lives of patients.

INNOVATION

We support innovative new technologies and start-ups that improve quality of care and healthcare outcomes.

HARMONISATION

We drive common approaches aligned with international best practices and standards to promote speed to access in a safe, secure, and ethical manner through the adherence to the Code of Conduct.

FOREWORD

" APACMed, with its unique regional reach and diverse membership spanning corporates and start-ups, acts as a critical bridge for the medtech ecosystem to collaborate and innovate so that patients can ultimately benefit from access to better technology."

John Collings

Chairman of the Board
APACMed

What a year 2024 has been! We celebrated our 10th anniversary with the theme of AI, highlighting both its opportunities and challenges. This year's **MedTech Forum** was truly special, bringing together 2,000 attendees from 28 countries and featuring 20 innovatively formatted sessions over two days. We welcomed 100 international speakers, including Nobel Prize laureate Malala Yousafzai, who emphasised the critical role of education in healthcare, as well as leading voices in healthcare AI, such as Tom Lawry and Dr. Brent James, who shared insights on AI's impact and the evolving role of talent in the healthcare landscape. We were also honoured to host Singapore's Senior Minister of State for Trade and Industry, Ms. Low Yen Ling, who reaffirmed the vital role of the MedTech industry in Singapore's economy.

In 2024, our **membership grew to 340**, spanning corporate, associate, and start-up members. We also recorded our highest-ever engagement, with **2,370 committee members** actively participating across nine committees, multiple working groups, and our two country offices. Thanks to the dedication of our members and partners, we published **18 papers** and reports and hosted **6,000 delegates across 82 events**.

I am particularly excited about the progress made under our newly established AI working group. Through this initiative, we forged a **key partnership with the Singapore Economic Development Board** to explore APAC's comparative AI talent landscape and how Singapore can position itself as a regional hub for MedTech AI capabilities.

Our **in-country advocacy efforts** continued to expand across 15 markets. This year, we hosted our first-ever Health Data Summit in Australia to advocate for data interoperability and organised value-based healthcare symposiums in Japan and Vietnam to advance discussions on the evaluation of medical devices. Additionally, we once again convened authorities from Japan, Korea, Australia, and Singapore to facilitate dialogue on digital health reimbursement challenges and best practices.

We concluded the year on a high note, receiving the **BioSpectrum Award** for Outstanding Leadership in MedTech Advocacy - a testament to the collective dedication of our members. By fostering collaboration and boldly championing innovation, APACMed is well-positioned to continue driving positive change and improving access to care for patients across the APAC region for years to come.

" Our advocacy efforts continue to build a pathway for access to care for patients in APAC. A healthier Asia is at the heart of all we do, and we want to be a catalytic partner to help make this a reality."

Harjit Gill

CEO, APACMed

In 2024, we had an exciting year in **policy advocacy**, achieving several key milestones that solidified APACMed's position as a trusted partner in policy formulation across the region:

- Our engagement with **Singapore's National Environment Agency (NEA)** led to a landmark exemption for critical substances such as Dechlorane Plus and UV-328, ensuring uninterrupted patient access to essential medical devices.
- In December 2024, following the national DRG 2.0 scheme releassd in August, Robotic-Assisted Joint Replacement Surgery was granted a new DRG payment group in **Zhejiang** - a major win for our members in the field.
- Another significant achievement was **our growing collaboration with governments** across the region. We were invited to work with key regulatory bodies, including China's National Medical Products Administration, Indonesia's Ministry of Health, and Malaysia's Medical Device Authority, to shape policies on electronic labeling, regulatory reliance, and change management.

Beyond advocacy, we continued to build capabilities across the ecosystem, particularly within ASEAN. In 2024, we trained over 1,000 regulators on key emerging regulatory issues. We also launched our **E-Learning Hub**, focused on regulatory training for APAC operations, and introduced new resources, including the **Integrated Resource Hub**, the **Regulatory Intelligence Bulletin**, and **Environmental Policy Dashboard 2.0**, which now covers nine markets - an expansion from six in 2023.

By 2030, one in four people in APAC will be aged 60 or older, while 700 million people in the region still lack basic healthcare support.

There is no denying that governments must prepare for the increasing strain on healthcare systems. Through meaningful engagement and knowledge sharing, we aim to help align APAC's regulatory and policy standards with global benchmarks - ensuring patients have access to quality care when they need it.

At APACMed, we remain passionate about being the voice of the MedTech industry. As we look ahead to 2025 and beyond, we are steadfast in our mission to enhance healthcare access and outcomes across APAC. Let us build on this momentum and continue transforming healthcare together in the years to come.

APACMED
IN NUMBERS

340
Members Strong

2,370
APACMed Committee Members

15
Markets Supported

18
Position & White Papers and Reports Published

20
Modules Released Since E-Learning Hub Launch

1,000
Regulators Trained

82
Events Held

With 6,000 Delegates Engaged

22,500
Social Media Followers
Growth Of 30% Since 2023

MEDTECH FORUM 2024 HIGHLIGHTS

2,000+
DELEGATES

28
COUNTRIES

2.2M
IMPRESSIONS

50,000+
ENGAGEMENTS

100
SPEAKERS

36
HOURS OF CONTENT

PAPERS PUBLISHED IN 2024

Advancing Patient Access to NGS for Cancer in APAC

APACMed Policy Memo – WHA Resolution 76.5 on Strengthening Diagnostics Capacity

Ethics Matter When Applying Artificial Intelligence to Medical Technologies Considerations for Asia Pacific

Realizing the Value of AI in MedTech in Asia Pacific

Establishing the Asia-Pacific Region as a Medtech AI Capability Hub

Fueling the APAC Medtech Innovation Engine An Ecosystem Investment

Risk-Based Change Management for Registered Medical Devices

Towards MedTech Efficiency & Sustainability through e-Label & e-IFU

APACMed Position Paper on Post-Market Surveillance and Vigilance



Value-Based Procurement in MedTech Pathways for Implementation in India Policy Brief

APACMed Digital Health Reimbursement Policy Forum 2024

APACMed Reimbursement Forum India Policy Brief

China "Two Sessions" and Trends in Value-Based Purchasing for Medical Devices

CN - Recommendations for Innovative Medical Technology under DRG Reform

Regulatory Landscape of Laboratory Developed Tests (LDT) in APAC

The Power & Promise of Health Data – Health Data Summit Australia 2024 Summary Report

Cybersecurity Incident Response Guides for Medical Device Manufacturers in Asia Pacific

Value-Based Market Access Symposium in Japan

Government Affairs and Policy

The Government Affairs and Policy Committee works with policymakers and other key stakeholders across the healthcare ecosystem to shape policy decisions that foster a conducive environment for MedTech industry to facilitate increased patient access in the Asia Pacific region.

Objectives of the Government Affairs and Policy Committee:

- Drive strategic collaboration between government, non-government and industry stakeholders to improve patient access to medical technologies.
- Advocate for striking a balance between fostering domestic resilience, promoting innovation and ensuring patient access to quality healthcare.
- Monitor key geopolitical developments globally and analyse the impact on the MedTech industry in APAC.

Our Leadership Team

BOARD SPONSOR

Feng Dong
Vice President,
Asian Region-Led Markets,
Global Regions

Medtronic

CHAIRPERSON

Shakilla Shahjihan
Divisional Vice President,
Government Affairs,
Asia Pacific & Japan

Abbott

VICE-CHAIRPERSON

Hui Sin Teo
Market Access and
Government Relations
Leader, Greater Asia

BD

VICE-CHAIRPERSON

Jane Mc Millan
Head of Government Affairs
& Policy Medtech, Asia Pacific

Johnson&Johnson

COMMITTEE LEAD

Benish Aslam
Lead, Government Affairs
And Policy & ESG

APACMed

Policy Initiative on Strengthening Diagnostics in Public Health

APACMed advocates for governments to invest in diagnostic capacity to enable early treatment, which helps them to manage the increasing disease burden in light of the region's demographic shifts, reduce healthcare costs, and improve pandemic resilience. Following the World Health Assembly (WHA)'s release of Resolution 76.5, which encourages countries to improve the availability and quality of diagnostics in low-resource settings, APACMed launched a policy memo supporting the need to prioritise diagnostics.

To contextualise the memo in Indonesia, in September 2024, we held a policy dialogue in Jakarta with Ministry of Health officials, local experts, and WHO representatives to discuss challenges faced by the government with respect to diagnostics infrastructure and access. The industry's role as a credible partner in developing quality cost-effective testing for underserved communities at scale was acknowledged. A follow-up closed-door dialogue in 2025 will target Indonesia's incoming cabinet to integrate diagnostics into its healthcare strategy.

Launch of GA Policy Intelligence Quarterly Webinar Series

APACMed launched quarterly webinars with external experts on geopolitical issues affecting the MedTech industry in APAC, equipping members with critical insight on key global policy developments. The inaugral session, focused on Indonesia's political transition and its impact on MedTech, covering regulatory shifts like localisation in the Omnibus Law and the JKN roadmap.

Submission of Local Content Calculation Methodology to Indonesia MOI

Amidst active industrial policies emerging across the region, APACMed has been highlighting the need for balanced domestic manufacturing policies to ensure patient access to quality care and innovation. APACMed submitted recommendations for Indonesia's Local Content Requirements (LCR) reforms, advocating for a phased, tiered approach in light of the availability (or lack thereof) of high-tech manufacturing capabilities, advocating for process-based calculations considering factors beyond manufacturing. Similar advocacy efforts are ongoing in Vietnam with respect to the upcoming medical device law.

Localisation Dialogue at MedTech Forum

USTDA Workshop in Vietnam


Closed-door Diagnostics Dialogue in Indonesia

Market Access Committee

The Market Access Committee works with policymakers, payors and other stakeholders across the healthcare ecosystem to advance access to innovative medical technologies for patients in the Asia Pacific region.

Objectives of the Market Access Committee:

- Advocate for the development of well-defined post-approval market access pathways through reimbursement frameworks.
- Facilitate the exchange of learnings and best practices among economies to foster collaboration, drive innovation, and strengthen healthcare systems.
- Champion the adoption of value-based healthcare to ensure equitable access to innovative medical technologies, improving outcomes for patients across the region.

Our Leadership Team



BOARD SPONSOR

Pavan Mocherla
Executive Vice President and President of the Greater Asia Region

BD



CHAIRPERSON

Arif Fahim
Regional Director Asia Pacific Global Health Economics & Reimbursement

Abbott

VICE-CHAIRPERSON

Josephine Hong
Head of Marketing, APAC

PHILIPS

VICE-CHAIRPERSON

Julian Sham
APAC Clinical Digital Transformation Lead, Roche Information Solutions

Roche

COMMITTEE LEAD

Anirudh Sen
Lead, Market Access, IVD

APACMed

Value-Based Market Access Symposium in Vietnam

Value-Based Market Access Symposium in Vietnam

Value-Based Market Access Symposium in Japan

Accelerating Digital Health Reimbursement in APAC

Reimbursement for digital health technologies in Asia faces significant hurdles, including fragmented schemes, unclear evidence requirements, and the lack of a unified framework aligned with international standards. To address these issues, the **APACMed Digital Health Reimbursement Policy Forum** was launched in 2023 as a collaborative platform. This initiative brought together payors, policymakers, academia, local trade associations, and industry leaders from APAC countries such as Australia, Japan, Korea, and Singapore, along with representatives from Europe, UK and the US, to explore the current landscape, challenges, and future directions for digital health reimbursement.

The forum aimed to foster open and constructive dialogue, generating actionable insights and recommendations for policymakers and industry stakeholders. By enabling peer-to-peer collaboration and promoting innovative approaches, the platform facilitated a deeper understanding of the complex challenges and identified potential solutions to advance digital health reimbursement in the region. In August 2023, the Korean Health Insurance Review and Assessment Service (HIRA) introduced ground-breaking updates to their national health insurance reimbursement guidelines, specifically tailored to accommodate digital therapeutics (DTx) and artificial intelligence (AI)-embedded technologies. These revised guidelines are designed to facilitate the rapid adoption of cutting-edge medical technologies, emphasising evidence generation through a comprehensive evaluation of innovative medical devices.

Promoting Value-Based Market Access in Japan and Vietnam

The MedTech industry continues to grapple with significant reimbursement cuts driven by cost pressures from ageing populations and shrinking healthcare budgets. In Japan, biennial reimbursement revisions do not fully recognise the essential value-added services provided by groundbreaking and innovative technologies. Similarly, in Vietnam, volume-based procurement practices hinder patient access to cutting-edge medical technologies.

To address these challenges and advocate for value-based healthcare, APACMed organised Value-Based Market Access Symposiums in Tokyo and Hanoi. These events brought policymakers together with industry leaders to explore best practices in value-based healthcare from global experts, emphasising the importance of enhanced value assessment frameworks.

Value-Based Market Access Symposium in Japan

Regulatory Affairs Committee

The Regulatory Affairs Committee spearheads regulatory excellence for optimised patient access to medical technologies, in close collaboration with regulators, policymakers, peers in other regions.

Objectives of the Regulatory Affairs Committee:

- Promote regulatory convergence and harmonisation to reduce market entry complexities.
- Elevate the industry regulatory capabilities, ensuring professionals possess comprehensive skills to promote standardised excellence in regulatory affairs.
- Advocate for flexibility to accommodate emerging innovative technologies and advancements.
- Provide timely insights, foster proactive industry engagement, and promote collaborative dialogues between regulators and manufacturers to enhance regulatory intelligence.

Our Leadership Team

BOARD SPONSOR

Paul Tan Minjie
Divisional Vice President, APAC

Abbott

CHAIRPERSON

Miang Tanakasemsub
Head of Regulatory Affairs Asia Pacific

Johnson&Johnson

VICE-CHAIRPERSON

James Chan
Regulatory Affairs Director, APAC

SIEMENS Healthineers

VICE-CHAIRPERSON

Jason Guo
APAC Director, Regulatory Affairs, Quality and Compliance

Abbott

VICE-CHAIRPERSON

Marianne Yap
Vice President, Quality, Regulatory and Government Affairs Asia Pacific, China & Japan

Alcon

VICE-CHAIRPERSON

Yasha Huang
Head of Regulatory Policy Asia Pacific Global Regulatory Policy & Intelligence

Roche



COMMITTEE LEAD

Cindy Pelou
Lead, Regulatory Affairs

APACMed

Fostering Collaboration and Insights: The 2024 Regulatory Affairs Forum

In 2024, APACMed's Regulatory Affairs Forum emerged as one of the standout projects for the year, garnering widespread praise from our RA members. The Forum showcased highly relevant topics, such as Predetermined Change Control Plan (PCCP) and Real-World Evidence (RWE), offering valuable insights for the MedTech community. Attendees benefited from engaging discussions, gaining a clear understanding of APAC regulators' 2025 priorities and strategies, while fostering strong industry-regulator connections. The event's networking sessions further enhanced collaboration, providing a unique platform to exchange ideas and build partnerships. The Forum underscored APACMed's commitment to advancing regulatory innovation and supporting members across the region.

Harmonising e-Label and e-IFU Regulations

Fragmented regulatory requirements for e-Label and e-IFU across APAC markets pose challenges for MedTech manufacturers in APAC. APACMed has attempted to address this matter through a position paper and an infographic that outlined actionable recommendations to harmonise these regulations. This advocacy effort influenced Indonesia's MOH to integrate English alongside Bahasa in e-IFU revisions and sparked interest from Thailand's FDA. Presented at the ASEAN Medical Device Conference, the initiative is notably driving regional momentum for alignment in ASEAN, paving the way for faster market access and operational efficiency for MedTech manufacturers.

APACMed China has submitted e-IFU paper and recommendations to NMPA, and will continue to support NMPA in exploring implementation in China.

Shaping Change Management Guidelines in Malaysia

Fragmented regulatory requirements for change across APAC markets pose challenges for MedTech manufacturers in APAC. APACMed has attempted to address this matter through a position paper and an infographic that outlined actionable recommendations to harmonise these regulations.

Starting with Malaysia, the country's current Change Management guidelines created challenges such as unclear definitions, prolonged approval timelines, and inadequate guidance for changes. To address these issues, the Malaysia's Medical Device Authority (MDA) partnered with APACMed through several capacity-building workshops, to align their guidance document to GHWP guidelines and other international frameworks.

This collaboration led to a co-development process where MDA is working with the MedTech industry to align guidelines with global standards. The initiative established APACMed as a trusted regulatory partner and set a precedent for regulatory co-creation in APAC. Moving forward, APACMed will support MDA in drafting updated guidelines through targeted workshops in 2025.

Change Management Workshop in Malaysia



e-IFU Engagement in Indonesia

Regulatory Affairs Forum in Singapore

Health Data Committee

The Health Data Committee works with policymakers and diverse stakeholders across the healthcare and information technology ecosystems to shape policies and processes that foster an environment that has strong cybersecurity frameworks and remains conducive to health innovation, ensuring continued patient access to quality care in the Asia Pacific region.

Objectives of the Health Data Committee:

- Health Data & Interoperability: To raise awareness on and work towards a common set of standards to optimise the utilisation of health data for innovation and improved patient outcomes.
- Cybersecurity: To raise awareness on and develop harmonised and robust cybersecurity frameworks against evolving cyber threats so that healthcare data is not compromised in an increasingly connected healthcare ecosystem.

Our Leadership Team

BOARD SPONSOR

Farhana Nakhooda

General Manager & Senior Vice President, Asia Pacific

Health Catalyst

CHAIRPERSON CYBERSECURITY

Paul Chua

Product Security Officer, Greater Asia

BD

VICE-CHAIRPERSON CYBERSECURITY

Joern Lubadel

Global Head of Product Security

B BRAUN

CHAIRPERSON INTEROPERABILITY

Shweta Bhardwaj

Director, Global Digital & R&D Policy

Johnson&Johnson

VICE-CHAIRPERSON INTEROPERABILITY

Virginia Chan

Head of Digitalisation, ASEAN

SIEMENS Healthineers

COMMITTEE LEAD

Su Fen Ong

Lead, Health Data

APACMed

Data interoperability Workshop in Indonesia

Advocating for Health Data Access in Australia

In 2024, APACMed focused on demonstrating the value of health data and ensuring ease of access within across Asia Pacific countries, with Australia as a priority market. Partnering with MTAA and supported by KPMG Australia, the Australia Health Data Summit brought together 40 leaders from government, industry, hospitals, and patient groups. Through keynotes and panel discussions, the summit emphasised the role of data sharing in improving patient care, driving policy, and fostering innovation. The summit fostered open discussions on health data access, real-world evidence for regulatory approval, and cybersecurity frameworks, setting the stage for further regional collaboration.

Advancing Interoperability in ASEAN Health Systems

To address the salient challenge of data interoperability in healthcare systems across the ASEAN nations, APACMed organised a Health Data Interoperability Workshop in Jakarta in June, convening ASEAN health IT officials and European experts from Integrating the Healthcare Enterprise. The workshop focused on practical steps for adopting common health data standards and improving data exchange frameworks. Participants received interoperability guidelines and best practices to enhance cross-border collaboration. This workshop was an instrumental step in promoting regional health data interoperability and fostering cooperation for future ASEAN health IT initiatives.

Building Cyber Resilience in MedTech

With evolving cyber threats, APACMed collaborated with Ensign InfoSecurity to create two cybersecurity guides: the Medical Device Product Security Incident Response Guide (Med-PSIRG) and the Cybersecurity Incident Response Guide (CSIRG). A hands-on Cyber Resilience workshop equipped MedTech companies with strategies to safeguard devices and respond effectively to cyber incidents. The guides and workshop offered a strong foundation for the industry to strengthen cyber resilience and enhance security in the digital healthcare ecosystem.

Cybersecurity Workshop in Singapore

Health Data Summit in Australia

Start-up Committee

The APACMed Innovation Community (AIC) serves as a MedTech innovation meeting ground for early- and mid-stage companies seeking support with scaling up, in the Asia Pacific region and beyond.

Key Activities of the Start-up Committee:

- Serving the SMEs: Training and capability development; Matchmaking of larger corporates and SMEs; Creation of SME zone at the annual APACMed MedTech Forum.
- Policy advocacy to improve the effectiveness and efficiency of MedTech innovation.
- Partnerships with leading accelerator programs and tradeshow events.

Our Leadership Team

BOARD SPONSOR

Marc Radatt
Chief Executive Officer,
Asia Pacific

OLYMPUS

CHAIRPERSON

Kris Liang
Strategy & Business
Development, Asia Pacific

stryker

VICE-CHAIRPERSON

Ashley Wittorf
Head of Business
Development, Asia Pacific

Johnson&Johnson

VICE-CHAIRPERSON

Lynne Lim
Founder &
Chief Executive Officer

NousQ

VICE-CHAIRPERSON

James Sung
Chief Executive Officer

MATRIXLabs Medical

VICE-CHAIRPERSON

Joaquin Lasso
SVP and General Manager
Sports Medicine, International

Smith+Nephew

COMMITTEE LEAD

Christine Tan
Lead,
Start-ups

APACMed

Start-up Showcase at MTF

Facilitating Partnerships Through the APACMed Innovation Community (AIC)

The AIC database played a key role in 2024, enabling valuable connections between MNCs and startups. Through its matchmaking efforts, APACMed provided members with opportunities to engage in conversations that fostered mutual understanding and exploration of potential collaborations. These efforts laid the groundwork for future partnerships and innovation-driven initiatives within the MedTech ecosystem.

The AIC database proved invaluable in 2024, supporting both MNCs and startups by enabling seamless connections. APACMed facilitated an average of one to two matchmaking requests weekly, providing members with opportunities to explore partnerships and collaborations. The steady flow of matchmaking requests helped foster meaningful conversations between MNCs and startups, creating a foundation for potential partnerships and innovation-driven collaboration.

Addressing SME Financing Challenges

In partnership with LEK, APACMed launched the whitepaper, "Fuelling the APAC MedTech Innovation Engine: An Ecosystem Investment" in September 2024. Highlighting a post-COVID-19 decline in venture financing and M&A deals - down 22% and 37%, respectively - the paper underscored the urgent need for enhanced investment in early-stage medtech innovation. It called for public-private collaboration to improve the investment climate and identified key ecosystem improvements to address inadequate capital allocation. The whitepaper emphasised APAC's pivotal role in global medtech innovation, raising awareness of the need for ecosystem investment to sustain life-saving advancements.



MedTech Forum 2024: Startup Zone

The 2024 MedTech Forum's Startup Zone empowered emerging innovators with resources, mentorship, and networking opportunities, supporting their growth and integration into the MedTech ecosystem. We also provided tailored support for startups through workshops and networking sessions:

- **Elevating Early-Stage Female Health Innovators:**
  Encouraged female founders to build healthcare startups.
- **MedTech Innovator Networking Breakfast:**
  Included a fireside chat with investors on U.S. market insights.
- **Scaling Mid-to-Late-Stage Innovation:**
  Highlighted connections between MNCs and SMEs.
- **Pitches by MedTech Innovator Finalists:**
  Gave startups a platform to showcase their innovations.

Artificial Intelligence (AI) Working Group

The AI Working Group was spun out of the Digital Health Committee in 2024, in order to place more emphasis on the emerging role of AI and MedTech in Asia Pacific. We are covering various forms of AI solutions (e.g., AI/ML, LLMs, GenAI, NLP, etc.) as well as both internal- (e.g., workflow) and external-facing (e.g., clinical) use cases. The Working Group is comprised of more than 50 companies (and growing), representing large and small organisations, actively collaborating together on AI policy matters in the region.

Objectives of the AI Working Group:

- Provide a voice on AI policy matters for the medtech industry in the region and timely intelligence to members on evolving AI policies and regulations that could impact their business.

Our Leadership Team

BOARD SPONSOR

Vy Tran
President,
Asia Pacific and Japan

SIEMENS Healthineers

COMMITTEE LEAD

Su Fen Ong
Lead,
Health Data

APACMed

Presenting the Value of AI in MedTech for APAC

The newly established AI Working Group made significant strides in 2024 by articulating the value of AI in the MedTech sector across APAC. APACMed, in collaboration with KPMG, released a whitepaper, "Realising the Value of AI in MedTech for APAC", which explores AI's potential to enhance efficiency, accuracy, and innovation in medtech. Centered around "Access," "Capability," and "Trust," the paper includes case studies and emphasised collaboration among industry, government, and academia to fully realise AI's potential. Key findings were presented at the 2024 MedTech Forum and a subsequent webinar, which attracted over 100 attendees, fostering meaningful dialogue. The paper serves as a foundational reference for stakeholders, setting the stage for future dialogues with stakeholders in the region.

Articulating the Impact of AI on MedTech Talent and Capability Development

Recognising the emerging talent needs and challenges posed by the rise of AI in MedTech, APACMed partnered with Bain & Company to release the whitepaper, "Establishing the Asia-Pacific Region as a MedTech AI Capability Hub". This report, supported by Singapore's Economic Development Board (EDB), identifies talent gaps and provided actionable strategies to address them through targeted training, cross-sector partnerships, and investment in AI education. The paper equips MedTech firms with insights to refine their talent strategies, ensuring the industry is prepared for the AI revolution, while gaining support from key stakeholders like Singapore's EDB.

Addressing Ethics in AI for MedTech

To tackle the ethical challenges associated with AI in MedTech - such as data privacy, algorithmic bias, and patient safety - APACMed released our POV, "Ethics Matter When Applying Artificial Intelligence to Medical Technologies: Considerations for Asia Pacific". Developed in partnership with K&L Gates, this concise document outlines key ethical considerations and frameworks to guide AI deployment. It emphasises transparency, accountability, and patient-centric approaches to build trust in AI systems. This thought leadership piece provides a solid foundation for collaborative efforts to address ethical concerns in AI adoption, fostering trust among stakeholders and reinforcing APACMed's commitment to responsible innovation.

Environment, Social, Governance (ESG) Working Group

The ESG Working Group advocates for a balance between environmental sustainability goals and maintaining access to essential medical devices and diagnostics in the region.

Objectives of the ESG Working Group:

- Educate members and other healthcare stakeholders on the evolving environmental regulations affecting the medical device industry in APAC, while co-developing a balanced MedTech-specific ESG narrative.

Our Leadership Team

BOARD SPONSOR

Vishnu Kalra
Company Group Chairman, Asia Pacific

Johnson&Johnson

COMMITTEE LEAD

Benish Aslam
Lead, Government Affairs And Policy & ESG

APACMed

Advocacy to Reverse NEA's UV-328 and Dechlorane Plus Hazardous Substances Ban

In response to Singapore's National Environment Agency (NEA) ban on UV-328 and Dechlorane Plus - originally set to take effect in February 2025 - APACMed led an advocacy campaign to address the significant disruption this posed to medical device supply chains. The team urged NEA to exempt all medical devices from the ban and extend the transition period by five years. APACMed collaborated closely with NEA, providing data on alternative substances, transition challenges, and international developments from Australia, Japan, and the EU. Support from the Economic Development Board (EDB), US Department of Commerce, and EuroCham further amplified the industry's position.

On October 11, 2024, NEA announced an indefinite exemption for these substances in all medical devices, recognising APACMed for its critical role in supporting their review. This exemption ensures continued access to essential medical devices in Singapore and underscores APACMed's critical role in balancing environmental goals with industry and patient needs. APACMed is currently building a database to support future advocacy on emerging regulatory challenges.

Updates to the Dashboard of Environmental Regulations for MedTech in APAC 2024

As ESG criteria increasingly influence financing and procurement decisions, navigating APAC's fragmented environmental regulatory landscape has become a priority for MedTech companies. To address this, APACMed released the second edition of its Environmental Regulatory Dashboard for MedTech in APAC, expanding coverage to nine markets with the addition of Singapore, Malaysia, and Thailand. The enhanced dashboard features a redesigned user interface, a summary page for quick overviews, drop-down filters, and a comparison tool for cross-market policy analysis. This comprehensive resource plugs a gap by equipping members with critical insights to navigate regulatory complexities, supporting compliance and strategic decision-making across the region.

Alliance Building With Trade Associations Globally

With climate change driving urgent action, APACMed joined the Global Medical Technology Alliance (GMTA) in forming a Sustainability Committee to enhance global collaboration. This committee focuses on information exchange around environmental sustainability, leveraging insights from trade associations across jurisdictions. Regular meetings have been established to share initiatives and identify opportunities for alignment. APACMed's participation in this global alliance enables the MedTech industry to address sustainability challenges collectively and align on best practices across borders.

In Vitro Diagnostics (IVD) Working Group

The IVD Working Group is a specialised group that focuses on issues related to in-vitro diagnostics (IVD) across key areas such as regulatory affairs, market access, and government affairs and policy. The working group is composed of representatives from various IVD member companies and experts in the field who collaborate to tackle industry challenges, advocate for supportive policies, and ensure that IVD products are both accessible and meet rigorous regulatory standards.

Objectives of the IVD Working Group:

- Emphasise the importance of diagnostics in healthcare and work towards driving better patient access to diagnostics in the Asia Pacific Region.

Our Leadership Team

BOARD SPONSOR

Lance Little
Head of Region,
Asia Pacific

Roche

COMMITTEE LEAD

Anirudh Sen
Lead,
Market Access, IVD

APACMed



Advancing Access to NGS for Cancer Care in APAC

Rising cancer rates in APAC pose significant societal and economic challenges. Next Generation Sequencing (NGS) has transformative potential for cancer care, but barriers like limited reimbursement and lack of value assessment hinder its adoption. To address this gap, APACMed developed a groundbreaking policy paper, "Advancing Patient Access to NGS for Cancer in APAC: Key Considerations and a Value Assessment Framework (VAF)." The VAF evaluates NGS's clinical, economic, and societal benefits, offering a practical tool for policymakers to enhance equitable access. By further holding a policy roundtable in Hong Kong, APACMed advocated for expanding NGS applications beyond lung cancer to other cancer types in the market. Discussions highlighted the lack of broad reimbursement and the need for robust value assessment criteria.

Overall, we positioned the VAF as a pivotal tool for evaluating NGS-based tumour profiling in APAC and led the way in fostering dialogue to address reimbursement gaps, setting the stage for broader adoption of NGS technologies in the region.

Next Generation Sequencing Activation in Hong Kong

APACMed China Office

The APACMed Beijing Office was officially established in August 2022. Since then, APACMed China has been dedicated to shaping an enabling ecosystem for innovation in China. In 2024, together with over 20 corporate members in 10 projects, including innovation pathways under the DRG reform, out-of-hospital care, capacity building, strategic regulatory topics, and regulatory reliance, APACMed China extended partnership with government agencies like NMPA, MOFCOM, as well as academia and HCP partners in China, presenting an ever-stronger industry voice. In 2025, APACMed China will continue to build on these achievements, offering valuable industry perspectives on critical topics and ensuring that the industry's voice is heard.

COUNTRY LEAD

Alicia Chang
Country Lead, China

APACMed

China Center Of Excellence Members

Regulatory Affairs

CHAIRPERSON

Annie Yin
Vice President Medical Regulatory Affairs

Roche

VICE-CHAIRPERSON

Jacqui Cui
Regulatory Affairs Director Global Strategic Regulatory

Abbott

VICE-CHAIRPERSON

Wang Ping
Senior Regulatory Affairs Manager, China

ResMed

VICE-CHAIRPERSON

Meng Qinghai
Associate Director Regulatory Affairs, China

Baxter

China Center Of Excellence Members

Government Affairs & Market Access

CHAIRPERSON

Anita Song
Director Of Health Economics, Policy and Reimbursement

Medtronic



VICE-CHAIRPERSON

Lilian Liang
Vice President, Government Affairs & Market Access

stryker

VICE-CHAIRPERSON

Jenny Jin
Senior Director, GA & QREM

FRESENIUS MEDICAL CARE

Shaping Out-of-Hospital Care Policies

In 2024, APACMed China focused on advancing out-of-hospital care policies to address the growing need for innovative medical solutions in non-traditional care settings. A significant milestone was the co-hosting of the "Harvard-Yangtze River Delta Age-Friendly Social Technology Innovation" forum in Shanghai. This event brought together over 200 participants, including government officials, industry leaders, and healthcare experts, to discuss innovations in out-of-hospital care. APACMed members showcased cutting-edge medical solutions and facilitated discussions with Singapore's Ministry of Health Transformation and Shanghai healthcare decision-makers. These engagements positioned APACMed as a leader in driving policy and innovation for out-of-hospital care in China. Looking ahead, the forthcoming "Out-of-Hospital Care Paper 2.0" will provide actionable recommendations to further shape this critical area.

Regulatory Reliance Advocacy

Recognising the lack of a clear regulatory reliance framework in China, APACMed China collaborated with the National Medical Products Administration (NMPA) to address this gap.

In September 2024, APACMed organised a regulatory reliance training session featuring global experts from Roche, J&J, and ResMed. The session highlighted best practices and recommendations for adopting reliance pathways. This engagement enabled APACMed to voice its position on regulatory reliance and laid the groundwork to foster an environment conducive to innovation and market access.

Promoting MedTech Innovation Ecosystem

To strengthen China's MedTech innovation ecosystem, APACMed co-hosted the "Forum on the Adoption and Development of Digital Health and Medical Technologies" during the Zhongguancun Forum in Beijing. The event gathered policymakers, scholars, and industry leaders to discuss key policies, including Beijing's action plan to become an international technology hub. APACMed launched two influential papers at the forum, focusing on AI in MedTech and innovation investment strategies. These initiatives underscored APACMed's commitment to fostering collaboration and driving innovation in China's healthcare landscape. China Daily covered the event.

Harvard-Yangtze River Delta Innovation Forum in Shanghai

Collaboration with NMPA on Regulatory Reliance

Forum on Digital Health Adoption in Beijing

APACMed India Office

The APACMed India Office was established in 2020 and comprises over 40 MedTech organisations as members. Committed to strengthening industry collaboration, APACMed has formed strategic partnerships with local trade associations and actively engages in key policy discussions. As a member of the Steering Committee of the National Medical Devices Promotion Council (NMDPC), we contribute to shaping the MedTech landscape and regularly participate in industry consultations organised by the Department of Pharmaceuticals (DoP) and the Central Drugs Standard Control Organisation (CDSCO). Operating through its Centre of Excellence, APACMed focuses on Government Affairs, Market Access, and Regulatory Affairs, ensuring a strong industry voice in India. The Centre of Excellence are led by an Executive Council composed of CEOs from Indian companies that are part of APACMed, reinforcing the organisation's commitment to advancing the MedTech sector in the country.

COUNTRY LEAD

Adip Puri
Country Lead, India

APACMed

India Exco Members

CHAIRPERSON

Shishir Agarwal
President and Managing Director

TERUMO



EXCO MEMBER

Tushar Sharma
Managing Director & GM India & South Asia

Abbott

EXCO MEMBER

Rishubh Gupta
Managing Director, India

Roche

EXCO MEMBER

Mandeep Singh Kumar
Vice President and Managing Director, India

Medtronic

EXCO MEMBER

Atul Grover
Managing Director, India & South Asia

BD

EXCO MEMBER

Aditya Banerjee
Managing Director, India

B|BRAUN

Addressing Compliance Challenges in India

In 2024, APACMed India took significant steps to address compliance and regulatory challenges faced by medtech companies in India. One key achievement was the establishment of the India Chapter of the Legal, Ethics, and Compliance (LEC) Committee. A CEO roundtable chaired by John Collings, Chairman of APACMed initiated this effort, bringing together 17 industry leaders to address key ethical and compliance issues. A follow-up meeting of LEC experts was held in September 2024 to take forward important issues of third-party risks and compliance challenges.

Enhancing Regulatory Clarity

APACMed's proactive advocacy during various industry consultations and meetings with the Indian regulatory body Central Drugs Standard Control Organisation (CDSCO) resulted in the publication of updated FAQs for medical devices. This updated FAQ streamlines regulatory processes, reduces query response times, enhances understanding of procedures, and assists the industry in improving dossier quality. These efforts exemplified APACMed's role in fostering greater clarity and efficiency within India's regulatory landscape.

Driving Stakeholder Engagement Through Key Events

A number of APACMed events in India brought together policymakers, industry leaders, and other stakeholders, reinforcing APACMed's leadership in shaping India's healthcare policies and practices. APACMed India organised a high-level closed-door roundtable to address the need for adopting Value-Based Procurement (VBP) for high-end medical devices. Furthermore, the second edition of the Reimbursement Forum, aimed at promoting transparent and inclusive HTA & reimbursement frameworks was organised in India. APACMed India also curated the second Digital Health Summit focused on the transformative potential of AI and health data.

Looking forward, the APACMed India COEs will continue to drive dialogue and collaboration to address critical healthcare challenges.

Reimbursement Forum 2nd Edition

CEO Meeting on Legal, Ethics and Compliance

Value Based Procurement Roundtable

MEDTECH FORUM
ASIA PACIFIC 2024



MTF 2024

THE DEC-AI-DE OF INTELLIGENT HEALTHCARE SYSTEMS

INTRO

The healthcare landscape in our region is rapidly evolving, demanding innovative solutions for the future. How can Artificial Intelligence (AI) unlock new opportunities to enhance patient care and optimise healthcare outcomes?

The Asia Pacific MedTech Forum 2024, held from 5-6 September in Singapore, placed a spotlight on AI and its transformative potential fuelling a more intelligent healthcare system.

Breaking the mold, this special 10th anniversary edition of the forum offered a dynamic experience unlike any before, fostering deeper interaction and collaboration. Delegates ushered in a new era of engagement enjoying 2 days of high impact content delivered by globally renowned speakers, connecting with people for idea exchange through interactive dialogue dens, and a buzzing Marketplace showcasing a compelling array of technologies.

Our Annual Flagship Event

HIGHLIGHTS

Our annual flagship event The Medtech Forum is the largest medical device conference in Asia, bringing together the global medical device community. In 2024, the Forum welcomed global dignitaries, CEOs, policymakers, innovators, and industry experts with over 2,000 delegates in attendance from around the world. For the first time in 2025, the Forum will be held in India.

2,000+
NUMBER OF DELEGATES

28
NUMBER OF COUNTRIES

100
NUMBER OF SPEAKERS

124
GOVERNMENT POLICYMAKERS

374
NUMBER OF HCPs

KEY SPEAKERS

Malala Yousafzai
Nobel Laureate, Co-Founder,
Malala Fund

Ms Low Yen Ling
Senior Minister of State,
Ministry of Trade & Industry and Ministry of Culture, Community & Youth

John Collings
Chairman, Board of Directors, APACMed
President, Asia Pacific, Stryker

Dr. Brent James
Clinical Professor, Clinical Excellence Research Center
Dept. of Medicine, Stanford University School of Medicine

Tom Lawry
Best-Selling Author, AI Transformation Advisor & Managing Director,
Second Century Tech

Matthew Luhn
Fortune 500 Storytelling Consultant, Disney/Pixar Veteran behind Toy Story, Monsters Inc., Finding Nemo, etc.

A/Prof Tam C. Nguyen
Deputy Director of Research, St Vincent's Hospital Melbourne
Associate Professor, Melbourne Medical School









KEY RESOURCES

We strive to empower our members with intelligence and timely updates on policy developments and regulations, helping them navigate an ever-evolving business landscape. This year, we launched and enhanced four key resources: the E-Learning Hub, Environmental Regulations Dashboard, Integrated Resource Hub, and Regulatory Intelligence Bulletin. Stay tuned for an even broader range of resources coming your way in 2025!

E-Learning Hub

In 2024, we launched our E-Learning Hub to offer the latest regulatory insights across APAC, drawing on the expertise of both regional and global industry leaders.

Environmental Regulatory Dashboard

Launched in 2023, the 2024 edition of the Environmental Regulations Dashboard tracks evolving policies across nine key APAC markets: Australia, China, India, Japan, Malaysia, Singapore, South Korea, Thailand, and Vietnam.

Regulatory Intelligence Bulletin

Released monthly via email, our regulatory intelligence bulletin provides members with APAC regulatory landscape update reports as well as key developments in the RA committee's projects.

Integrated Resource Hub

Launched in 2024, the integrated resource hub provides members with a one-stop platform to access all our resources including industry position papers, reports, dashboards, and webinars.

OUR MEMBERS

Membership Benefits

- Join a collective voice dedicated to advancing healthcare in the Asia Pacific by enhancing care standards, expanding access, and fostering collaboration.
- Engage with senior executives in Functional Committees and Working Groups, participate in exclusive workshops, seminars, CEO Roundtables, and networking events, and take part in the annual Asia Pacific MedTech Forum - the region's most influential industry gathering.
- Gain access to exclusive market insights and analysis from APACMed Knowledge Partners, receive timely updates on regulatory and policy developments with strategic guidance, and leverage extensive resources available in the Members-only section of our website.

Membership Category

Corporate
Corporations manufacturing and conducting R&D in medical equipment, devices, in vitro diagnostics or digital health solutions with global annual sales above USD 50 million.

Start-ups & SMEs
Start-ups or SMEs manufacturing and /or conducting R&D in medical technology with annual sales less than USD 50 million.

Associate
Service Providers including consultants, contract manufacturers, CROs, investors, distributors, recruiters, lawyers and etc.

Industry Association
National Associations representing the interests of the medical technology industry in any country in Asia Pacific.

Corporate Members

Associate Members

Access Partnership
Accenture
Alira Health
AMT (Alliance BioMed)
Ansea
Aptyx (GlobalMed)
ARQon
Ascential Medical & Life Sciences
Avalere Health (PRMA Consulting)
Bain & Company
Baker Mckenzie
Barrington James
Beyonics
Biomed Global
Bird & Bird
Boston Consulting Group (BCG)
Catcher Technology (Cor Ventures)
Clarivate
Collab Novena
Conray Medical
Cytel
DCH Auriga
Deloitte
Digital Therapeutics Alliance
DKSHI
DSM Biomedical Sciences
DTG Medical
EPM Scientific
Eversana
Geeta Thakerar Consultancy
Getz Healthcare
Graham Engineering
Indegene
IPSOS Healthcare
IQVIA
JAS Worldwide
JLK Technology
Johari Digital Healthcare
K&L Gates
Korn Ferry
KPMG
LEK
McKinsey
MDREX
MedAsian
Medline Industries
MedSec
Medtech Actuator
MedTech Innovator mediPr
Messe Duesseldorf Asia
MURSMEDIC
NKG Advisory Business & Consulting
Services
Oliver Healthcare Packaging
Opulent
PSA BDP
PTC
PureHSA
Rook Quality Systems
ROPES & GRAY
SANTOMAS VIETNAM
ShenZhen FULIDA Industrial
Singapore Biodesign
SPAG
Syensqo (Solvay Specialty Chemical)
T&C Law Firm
The Mullings Group
Transmedic
TTP
Turacoz
UPS Healthcare
Vista Health Consulting
Vriens & Partners
White Rook Advisory
World Courier
ZS Associates
Zuellig Pharma

Industry Association Members

Austrade
Association of Malaysian Medical Industries
Biotech Connection Singapore
China Chamber of Commerce for Import and Export of Medicines and Health Products
Gakeslab Indonesia
Healthcare Devices Association of Pakistan
Healthcare Technology Association of the Philippines
High Commission of Canada
Hong Kong Medical and Healthcare Device Industries Association
Institute for Biotechnology and Medicine Industry (IBMI)
Israel Economic and Trade Mission
Korea Medical Devices Industry Association (KMDIA)
Medical Technology Association of Australia (MTAA)
MCCPMO
New Zealand Trade & Enterprise
Philippine Association of Medical Device Regulatory Affairs Professionals (PAMDRAP)
Polish Investment & Trade Agency Scottish Development International
Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association
Sri Lanka Chamber of Medical Devices Industry
Trade and Investment Queensland

Start-up & SME Members

3R Innovation
7Apricot Agape-Life
ABM Respiratory Care
Adiuvo Diagnostics
Advanced Biomedical
Advanced Health Intelligence (AU)
Advante Medica
Adventa
AiHealth.SG
Ainex Corporation (KR)
AIRS Medical
Aitrics
AIVIS
Aktivolabs
Analytica
Anode
apoQlar
APrevent (TW)
Arien Technologies
Armastec
Asensus Surgical
Astron Medtech (TW)
AISI X
Biomedia Holdings
Biorithm
Blue Oak
Bot MD
CAREFUL Systems
CareMonitor
Castomize Technologies (SG)
Cogni.Dx
Connect2MyDoctor by Neev Labs
CosmoAesthetics (AU)|
Creative Biosciences
Crely
Cyclops MedTech
DAWONMEDAX (KR)
DEEPNOID
Digital Life Line (SG)
Digostics (UK)
EHUAKING (CN)
Elfie
Envisionit Deep Al
ErleaDx
EverEx
FathomX Fitterfly
FlexoSense
Flomatrix (AU)
F.MED
Gellycle
Geneus Technologies (CN)
GenLight MedTech (CN)
GERMITEC
Gyder Surgical
GyroGear
Haemetrics
Healium Medical HealKEE Medical
HealthBeats
HiCura Medical
HiDoc
Holo4Med iCaltech Innovations
IceCure Medical icliniq.com
iMedrix Infervision
InnAccel Technologies
INOPASE (JP)
iXensor
JD Sanmed
Jonda Health
KA Imaging (Canada)
Kinexcs
KingoBio
KM Medical
KnitFit
Kriya Medical Technologies
Lenexa Medical
Lifespans
LUCID Implants
Lumio 3D
MATRIXLabs Medical
Medipixel
Medi Whale
Medicaretec MediHeroes
MEDO.ai
MedPiper
Medtrik (SG)
Megasoft
MEINNTECH
Meracle (SG)
MiXRES
Mode Sensors
Module Innovations mSurgey
Naluri
Near Brain
Nesa MedTech
Neurofrog
Neurowyzr (SG)
NexRea
NousQ
nPlasty
Nu Eyne
NUA Surgical
NUBENTOS
Nuroflux
Nusantics
Onco-Connect
ONWARD Health Research (SG)
Opharmic Technology
Orbit Health
Ossfila Technology
Peach Health Asia (SG)
Peijia Medical
Perimed Instruments
Peth Young
PrimaNova Technologies (HK)
PROMinsight
Progress Magic (SG)
Pryfiber (UK)
Pulnovo Medical aritive
Rebee
Regeneus
Rehabotics Medical Technology
Remidio (IN)
Restorative Therapies
Riverr (SG)
Roceso Technologies
Ruishi Health Technologies (CN)
RWG
Sevamob
SG Diagnostics
ShadeOfThings
SmartRx (SG)
So Healthful Innovations
Sound Mate
Sporogenics (SG)
STASIS
SuperVision
SwiftDoc
Tech Doctor
T'ena Health Technologies
TeleMedC
The Clinician
Thrixen
Triphasic Cardiac Pump (AU)
Trisafe Health Tech
TriSail Medical
TruScreen
UroMedTech
Ventas Bio
Vesica Al
Vidcare Innovations
Vigor Medical Systems
VinBrain
VirtualiSurg
VisionHealth
Vivo Surgical (SG)
Volition
VPIX Medical
Vulcan Augmetics
VUNO
Waycen (KR)
Wearne Digital
WeGuide
Well Being Digital (WBD101)
Welsmeditech
WELT
Wetling Health
WOEX (SG)
Xinguang Bio-Pharmaceutical
X-ZELL
Zealthlife
Zenyum
Zevigo Solutions

BOARD OF DIRECTORS

Experience and Expertise

Our board members from our member companies equip us with critical insight into our work in the MedTech industry.

John Collings

Chairman

President,
Asia Pacific
Stryker

Probir Das

Vice-Chairman

Group Excecutive Officer,
Terumo Corporation
Chairman, Regional Rep.
Terumo Asia Holdings

Lam Chee Hong

Treasurer

President,
Asia Pacific
B. Braun

Farhana Nakhooda

General Manager & Senior
Vice President, Asia Pacific
Health Catalyst

Feng Dong

Vice President, Asian
Region-Led Markets,
Global Regions
Medtronic

Vy Tran

President of Asia
Pacific and Japan
Siemens Healthineers

Stephen Morse

Senior Vice President &
President, Asia Pacific
Boston Scientific

Paul Tan Minjie

Divisional Vice President,
Asia Pacific
Abbott Vascular

Pavan Mocherla

Executive Vice President &
President Greater Asia
Becton Dickinson

Lance Little

Head of Region
Asia Pacific
Roche Diagnostics

Marc Radatt

Chief Executive Officer
Asia Pacific
OLYMPUS

Punit Kohli

Vice President-Commercial
Operations, Asia Pacific
Fresenius Medical Care

Vishnu Kalra

Company Group
Chairman, Asia Pacific
Johnson & Johnson MedTech

APACMED SECRETARIAT

Harjit Gill
Chief Executive Officer

Gabriel Sim
Director, Strategic Partnerships

Christine Tan
Lead, Start-ups

Anirudh Sen
Head, Market Access Lead, IVD

Nishan Pillai
Head, Finance and Operations
Lead, Legal, Ethics & Compliance

Alicia Chang
Country Lead, China

Adip Puri
Country Lead, India

Benish Aslam
Lead, Government Affairs and Policy & ESG

Su Fen Ong
Lead, Health Data

Cindy Pelou
Lead, Regulatory Affairs

Ankit Sharma
Manager, India

Shreya Bansal
Associate, India

Devya Bharati
Associate, Regulatory Affairs

Zoey Ma
Associate, China

Kamalesh Logarajan
Associate, Finance and Administration

Cissy Chen
Head, Creative and Design

Grace Chua
Manager, Events Marketing

Binderiya Makhbal
Project Manager, Market Access

Jordan Lee
Project Manager, Government Affairs

Shinae Baek
Head, Communications

Sheena Suthen
Project Manager, Market Access

Harjit Gill

Gabriel Sim

Christine Tan

Anirudh Sen

Nishan Pillai

Alicia Chang

Adip Puri

Benish Aslam

Su Fen Ong



Cindy Pelou

Ankit Sharma

Shreya Bansal

Devya Bharati

Zoey Ma

Kamalesh Logarajan

Cissy Chen

Grace Chua

Binderiya Makhbal

Jordan Lee

Shinae Baek

Sheena Suthen

Make innovative medical technology available to more people in Asia-Pacific.

APACMed

The voice of MedTech

Annual Report 2024